Another randomized control trial found that curcumin nanomicelles administration to COVID‐19 patients decreased the serum level of IFN‐γ and IL‐17 while increasing the levels of IL‐4 and TGF‐β compared to the placebo group. The gene discussed is TGFB1; the disease is COVID-19.